menu
    • menu
    [{"orgOrder":0,"company":"AliveGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ALG-801","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"AliveGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"AliveGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AliveGen \/ Not Applicable"},{"orgOrder":0,"company":"AliveGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"ALG-801","moa":"Smad2\/3 pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AliveGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AliveGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AliveGen \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by AliveGen

    Menu

    AliveGen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AliveGen

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            AliveGen

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALG-801

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AliveGen Receives FDA Orphan Drug Designation for ALG-801 in Pulmonary Hypertension

                            Details : ALG-801 is a novel ActRIIA/IIB hybrid ligand trap designed to selectively sequester a specific set of Smad2/3 pathway-activating ligands, critically involved in the pathogenesis of PAH.

                            Product Name : ALG-801

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : ALG-801

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AliveGen

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            AliveGen

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALG-801

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AliveGen Completes Phase 1b Trial for ALG-801 Multiple Dosing

                            Details : BIIB110 (ALG-801) is a next-gen ligand trap that selectively sequesters TGF-beta family members. It's evaluated for muscle wasting, metabolic disorders, and neuromuscular diseases.

                            Product Name : BIIB110

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 18, 2024

                            Lead Product(s) : ALG-801

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth